TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

5A.149 Hartzell JD et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment
at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8.
5A.150 Falagas ME et al. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009;
48:1729-31.
5A.151 Wahby K et al. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 2010;
50:e38-40.
5A.152 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect
Ther 2006;4:947-52.
5A.153 Herrmann DJ et al. Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect
Ther 2008;6:825-48.
5A.154 Falagas ME et al. Linezolid versus glycopeptide or β-lactam for the treatment of Gram-positive bacterial
infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66.
5A.155 De Vriese AS et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis
2006;42:1111-7.
5A.156 McKee EE et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob
Agents Chemother 2006;50:2042-9.
5A.157 Stevens DL et al. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther
2004;2:51-9.
5A.158 Bassetti M et al. Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect
Ther 2005;3:343-52.
5A.159 Razonable RR et al. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004;79:1137-44.
5A.160 Wu VC et al. High frequency of linezolid-associated thrombocytopenia and anemia along patients
with end-stage renal disease. Clin Infect Dis 2006;42:66-72.
5A.161 Attassi K et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-8.
5A.162 de Antonio JM et al. Thrombocytopenia and anemia associated with linezolid in patients with kidney
failure. Clin Infect Dis 2006;42:1500.
5A.163 Apodaca AA et al. Linezolid induced lactic acidosis. N Engl J Med 2003;348:86-7.
5A.164 Bressler AM et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect
Dis 2004;4:528-31.
5A.165 Linam WL et al. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J
2009;28:149-51.
5A.166 Frippiat F et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob
Chemother 2004;53:1114-5.
5A.167 Saijo T et al. Linezolid induced optic neuropathy. Am J Ophthalmol 2005;139:1114-6.
5A.168 Lawrence KR et al. Serotonin toxicity associated with the use of linezolid: a review of post-marketing
data. Clin Infect Dis 2006;42:1578-83.
5A.169 Taylor JJ et al. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis
2006;43:180-7.
5A.170 Wigen CL et al. Serotonin syndrome and linezolid. Clin Infect Dis 2002;34:1651-2.
5A.171 Bernard L et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin
Infect Dis 2003;36:1197.
5A.172 Hammer MC et al. Linezolid-induced acute interstitial nephritis. Infect Dis Clin Pract 2009;17:61-2.
5A.173 Velema MS et al. DRESS syndrome caused by nitrofurantoin. Neth J Med 2009;67:147-9.
5A.174 Forrest GN et al. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev
2010;23:14-34.
5A.175 Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect
Dis Clin North Am 2004;18:669-89.
5A.176 Strevel EL et al. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet
Infect Dis 2006;6:178-82.
5A.177 Masters PA et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10.
5A.178 Strevel EL et al. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet
Infect Dis 2006;6:178-82.
5A.179 Trepanier LA et al. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole
nitroso in HIV infection. J Acquir Immune Defic Syndr 2004;36:1041-50.
5B.1 Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000;
46(topic T1):17-24.
5B.2 Van Bambeke F et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80.
5C.1 American Academy of Pediatrics Committee in Fetus and Newborn. Age terminology during the perinatal
period. Pediatrics 2004;114:1362-4.
5C.2 Henry NK et al. Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient
practice of pediatric infectious diseases. Mayo Clin Proc 2000;75:86-97.
5C.3 American Academy of Pediatrics Committee on Infectious Diseases. Antibacterial drugs for pediatric
patients beyond the newborn period. Red Book 2009;28:747-57.
5C.4 Bowlware Kl et al. Antibacterial agents in pediatrics. Infect Dis Clin North Am 2004;18:513-31.
5C.5 Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect
Ther 2006;4:853-60.
5C.6 Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19:
617-28.
5C.7 Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr
Infect Dis J 2007;26:865-7.
5C.8 Gendrel D et al. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet
Infect Dis 2003;3:537-46.
5C.9 Tamma P et al. Use of colistin in children. Pediatr Infect Dis J 2009;28:534-5.
5C.10 Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010;29:462-4.
5C.11 Frymoyer A et al. Current recommended dosing of vancomycin for children with invasive methicillinresistant
Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402.
5C.12 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect